Biora Therapeutics has filed a patent for methods and compositions to treat gastrointestinal tract diseases using a TNF-alpha inhibitor. The patent claim has been canceled. GlobalData’s report on Biora Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Biora Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Biora Therapeutics, Ingestible drug delivery devices was a key innovation area identified from patents. Biora Therapeutics's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

Treating gastrointestinal diseases with a tnf-alpha inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Biora Therapeutics Inc

A recently filed patent (Publication Number: US20230312700A1) describes a method for treating gastrointestinal (GI) inflammatory diseases or conditions. The method involves topically administering a pharmaceutical formulation containing a TNF inhibitor to a subject in need. The administration can be done orally using an ingestible device that releases the formulation either to a specific section or subsection of the subject's GI tract containing inflammatory disease sites or proximal to those sites. This targeted administration aims to treat at least one of the disease sites effectively.

The patent also introduces a self-localization mechanism within the ingestible device to determine its location within the subject's GI tract. This mechanism helps in accurately determining the device's position within the GI tract. It achieves this by detecting transitions between different portions of the GI tract, such as the mouth and stomach, esophagus and stomach, stomach and duodenum, and others. The self-localization mechanism aims to achieve an accuracy of at least 80% in determining the device's location.

Furthermore, the patent describes the release of the pharmaceutical formulation from the device being autonomously triggered based on the self-localization of the device to a pre-selected location within the subject's GI tract. The pre-selected location can be the stomach, duodenum, jejunum, ileum, cecum, ascending colon, or traverse colon. The release of the formulation occurs simultaneously with the device's self-localization to the pre-selected location.

The patent also mentions the use of a TNF-alpha inhibitor, such as adalimumab or its biosimilar, as the therapeutically effective agent in the pharmaceutical formulation. The formulation can be released from the device at a ratio ranging from about 2:1 to about 3000:1 in terms of concentration in the subject's GI tissue compared to their blood, serum, or plasma concentration. The method can be used for both induction and maintenance doses of the TNF-alpha inhibitor.

Additionally, the patent describes an ingestible device specifically designed for treating inflammatory gastrointestinal diseases or conditions. The device includes a pharmaceutical formulation, processing devices, and machine-readable hardware storage devices. These components work together to determine the device's location within the subject's GI tract and release the formulation at a pre-selected location. The device aims to achieve an accuracy of at least 80% in self-localizing to the pre-selected location.

Overall, this patent presents a method and ingestible device for targeted treatment of GI inflammatory diseases or conditions using a TNF inhibitor. The self-localization mechanism within the device ensures accurate positioning, and the autonomous release of the formulation enhances the effectiveness of the treatment.

To know more about GlobalData’s detailed insights on Biora Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies